Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT05465200
Recruiting Observational

Lower Silesia Cardiogenic Shock Initiative

NCT05465200 · tracked via the Priya Life Science Poland tracker
Sponsor
Wroclaw Medical University
Phase
Observational
Started
2022-01-01
Last updated
2025-04-02

Condition(s) studied

Cardiogenic Shock

Investigational drug(s) / intervention(s)

Structured treatment of cardiogenic shock patients

Structured treatment of cardiogenic shock patients: Creation of hub\&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to "hub" by "spoke" and decision is made as for patient transfer or further treatment in the "spoke" facility. If decision on transfer is made, patient is further treated according to "hub" on site shock team protocol

Study summary

LSCSI is a Hub\&Spoke project with the main aim to improve the outcome of patients with cardiogenic shock in Lower Silesia region, Poland. It consists of one "hub" which is Wroclaw University Hospital and eleven "spokes" which are eleven cardiology departments situated in Lower Silesian Voivodeship. The consortium have unified protocol defining which cardiogenic shock patient and when should be transferred to the "hub" for enhanced treatment options including durable mechanical circulatory support or heart transplant. The "hub" have 7/24 Shock Team on-site supplied with a protocol how to proceed with "spoke" transferred patients including decision making on which mechanical circulatory support implant with subsequent de-escalation or escalation pathway.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: 1. Fulfilled definition of cardiogenic shock 2. Age 18 - 60 years 3. Shock duration below 24 hours Exclusion Criteria: 1. History of cardiac arrest with anoxemic brain injury 2. Irreversible multiorgan failure 3. End stage of chronic diseases other than heart failure 4. Neoplastic disease 5. Lack of vascular access

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institute of Heart Disease of Wroclaw Medical University Wroclaw Poland Recruiting

More Wroclaw Medical University trials in Poland

The Impact of Expandable Cryoballoon on Autonomic Control of the Heart Active, not recruiting
Effectiveness of iPRF Injections in Temporomandibular Joints Degeneration Management Enrolling by invitation
Selected Disorders and Sleep Bruxism Enrolling by invitation
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin Enrolling by invitation
Evaluation of the Factors Associated With BRADYcardia Following Pulmonary Vein Isolation Using Pulsed Field Ablation Recruiting

Other trials for the same condition

Polish Nationwide Registry of Diagnostics, Treatment and Outcome in Patients With Cardiogenic Shock Recruiting
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05465200 on ClinicalTrials.gov ↗ ← All trials in Poland